Zokinvy is a medicine used to treat patients of 12 months and older who are affected by the following rare diseases in which features resembling aging appear in childhood: - Hutchinson-Gilford progeria syndrome; - processing-deficient progeroid laminopathies. The diseases that Zokinvy is used to treat are rare and Zokinvy was designated as ‘orphan medicine’ on [14 December 2018](/en/medicines/human/orphan-designations/eu-3-18-2118) for Hutchinson-Gilford progeria syndrome. Zokinvy contains the active substance lonafarnib.
Therapeutic Indication
### Therapeutic indication Zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of Hutchinson-Gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous LMNA mutation with progerin-like protein accumulation or a homozygous or compound heterozygous ZMPSTE24 mutation.
Therapeutic Area (MeSH)
N/AATC Code
N/A
ATC Item
N/A
Pharmacotherapeutic Group
Other alimentary tract and metabolism products
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| Lonafarnib | N/A | Lonafarnib |
EMA Name
Zokinvy
Medicine Name
Zokinvy
Aliases
N/ANo risk management plan link.
